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Population-based studies indicate that psoriasis associates 
a greater risk of comorbidities that alter mood, such as 
anxiety and, above all, depression. We applied a complete 
panel of validated questionnaires to perform a full psycho-
pathological exploration according to the DSM-V classifica-
tion of psychiatric diseases in 300 psoriatic patients. A do-
se-response association with depression and anxiety (the 
more severe psoriatic patients have more risk of having 
depression or anxiety) was observed. The Montgomery-
Asberg Depression Rating, Hamilton Rating for Depression,  
Hospital Anxiety and Depression scales (for depression), 
and State Anxiety Inventory (for anxiety) seem to better 
detect such mood comorbidities in psoriatic patients.
Psoriasis is a chronic skin disease associated with con-
siderable physical and psychological comorbidities. 
Stress and emotional disturbances have been impli-
cated in both triggering the onset and exacerbation of 
psoriasis. In order to determine the level of perceived 
stress and mood alterations in patients with psoriasis 
and their association with disease severity, 300 indi-
viduals completed diverse validated questionnaires as-
sessing stress and psychological mood. Evaluation of 
perception of disease was also measured. A significant 
association between psoriasis severity and mood, emo-
tional disturbances and an impact on assessments of 
the quality of life were observed. Particularly, Montgo-
mery-Asberg Depression Rating Scale, Hamilton Rating 
Scale and Hospital Anxiety and Depression Scale for 
Depression detected a significant risk for depression 
in relation to the disease severity. The association bet-
ween depression features, anxiety and perceived stress 
with psoriasis severity is important and can influence 
the appropriate management of psoriasis.
Key words: psoriasis; anxiety; depression; stress; mood; quality 
of life.
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Psoriasis affects about 2.3% of the Spanish popula-tion. An increasing prevalence has been detected, 
probably due to a higher awareness and earlier diagnosis, 
rather than an increment of the total number of cases (1, 
2). Individuals are likely to present differing levels of 
disease severity throughout their lifetime, experiencing 
‘spontaneous’ remissions and flare-ups during the disease 
course. The pathogenesis of psoriasis is not fully under-
stood but includes hereditary and environmental factors.
Psoriasis is considered to be a psycho-physiological 
disease, a dermatological condition which evolution may 
be influenced by psychological aspects. Patients often 
point out stress as an exacerbating factor. Some studies 
support the fact that stress may play a relevant role in the 
onset and course of psoriasis in comparison with other 
conditions, such as urticaria or atopic dermatitis (3, 4). 
Relationships between emotional stress and psoriasis se-
verity have been reported and a conclusive link between 
skin symptoms and mood was demonstrated (5). More-
over, large-scale studies have evaluated the association 
between depression, anxiety and suicidal ideation with 
psoriasis. A significantly higher prevalence of psycholo-
gical and psychiatric disorders in patients suffering from 
psoriasis has been reported (6–8).
The present study aims to assess the impact of psycho-
social events or mood disorders on the psoriatic population 
and to explore their link to the quality of life (QoL) and 
health status related to skin disease severity. To accom-
plish this, both stress level (secondary to recent-previous 
life events) and current psychological co-morbidities were 
measured among psoriatic individuals with different levels 
of skin disease severity using a complete set of validated 
questionnaires. In contrast to other studies, a large number 
of cases were evaluated, using an efficient methodology 
to record stressful life events and psychological mood 
variables. The impact of the stress level on the severity of 
psoriasis, considering both the physician and the patient’s 
points of view was also assessed. 
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PATIENTS AND METHODS
This observational study recruited 300 psoriatic adult patients, who 
completed a set of validated questionnaires assessing perceived 
stress of known origin, or associated with disorders of the psy-
chological mood. This study was conducted at the Department of 
Dermatology in a tertiary referral center in Barcelona over a period 
of 18 months and was approved by the institutional ethics commit-
tee. The study population included outpatient representative for 
the psoriasis population since almost all patients with moderate 
to severe psoriasis in our geographical area are evaluated in our 
center. Exclusion criteria included diagnosis of severe uncontrolled 
psychiatric disorders (i.e. schizophrenia or bipolar states) and/or 
presence of difficulties in comprehension or communication or 
psychiatric treatments that may influence the course of psoriasis 
severity (i.e. lithium salts). The socio-demographic and clinical 
variables collected in this study included: sex, age, psoriasis sub-
type, disease duration, frequency of exacerbations, and presence 
of arthritis and nail psoriasis. Pain and itching symptoms, related 
to the skin disease; smoking or alcohol intake and presence of 
obesity, as other elements related to the psoriasis severity, were 
also recorded.
The survey measured the psycho-emotional status. Stressful 
life events were evaluated using Holmes and Rahe’s Social 
Readjustment Rating Scale or Life Events Scale (LES) (9). LES 
describes situations, which generate stress in the majority of the 
population. According to a scoring system, which includes 43 
items and evaluates a period of 12 months, patients are classified 
into 3 categories: mild, moderate or severe stress. 
Hospital Anxiety and Depression (HAD) Scale was used to 
measure anxiety and depression (10). Hamilton Rating Scale for 
Depression (HRSD) and Montgomery-Asberg Depression Rating 
Scale (MADRS), as a clinician-administered measure for depres-
sion, were also utilized (11, 12). Spielberger State-Trait Anxiety 
Inventory (STAI) was administered to the participating subjects 
and the differences in State Anxiety Inventory (SAI) and Trait 
Anxiety Inventory (TAI) were analyzed (13).
The impact of disease on health-related quality of life (HRQoL 
was measured using the Mental (MCS) and Physical (PCS) 
Component Summary scores of the SF-12, and Dermatology 
Life Quality Index (DLQI; score of 0–30) (14, 15). DLQI is a 
dermatology-specific 10-item questionnaire that considers aspects 
of the impact of skin disease on a patient’s QoL in the preceding 
week, which was filled in by the patients themselves. They used a 
Likert scale with 4 alternatives to evaluate the impact of disease on 
HRQoL. Additional measurement included the 0–100 mm visual 
analogue scale (VAS) for pruritus evaluation.
Two dermatologists, using the Psoriasis Area and Severity 
Index (PASI), Body Surface Area (BSA) and Psoriasis Disability 
Index (PDI) (16), evaluated the severity of psoriasis. The rule of 
tens (PASI, BSA and DLQI indexes) was used as the reference 
for considering the severity of psoriasis as mild, moderate or 
severe (17, 18).
Statistical analysis
The data were analyzed in relation to 2 groups separated on the 
basis of the severity of the psoriasis: moderate–severe psoriasis (pa-
tients with PASI ≥ 10 or BSA ≥ 10 or DLQI ≥ 10) and mild psoriasis 
(patients with , < 10 and BSA < 10 and DLQI < 10). Student t-test 
and χ2 tests were used for continuous variables and categorical vari-
ables, respectively, in order to compare the different characteristics 
between the two groups. Logistic regression was calculated for the 
indexes of psychological stress and severity of psoriasis, as well 
as for the psychological stress indexes and visibility of psoriasis, 
adjusted for all confounding factors. Calculations were performed 
using the statistical package Stata/SE 12.1 (Texas, USA).
RESULTS
Demographics
The sample included 300 patients (47.3% men, 52.7% 
women) from 18 to 89 years of age (mean = 49.7). The 
median number of years patients suffered from the 
disease was 13. The majority of patients (62%) had a 
classical plaque form of the disease. Specific localized 
forms of the disease were present in 48% of cases (palmo-
plantar: n = 45 or scalp psoriasis: n = 101). Thirty percent 
of patients had one or more flares, needing additional 
treatment, during the last year and in 209 cases psoriasis 
was considered to be chronic with a stable clinical course. 
Pruritus was significantly related to disease severity. The 
clinical features of the disease, the presence of arthropa-
thy or nail involvement are detailed in Table SI1, stratified 
by the severity of the skin disease.
Psoriasis severity subgrouping
Disease severity, established using Finlay’s rule of tens, 
in our cohort was as follows: 184 (61%) patients were 
considered to have moderate-severe psoriasis, whereas 
116 cases (39%) were considered to have mild disease. 
The mean ± standard deviation (SD) PASI score was 
13.0 ± 8.5 and mean BSA 23 ± 13.6%. In the mild se-
verity group, there was a female predominance (56%) 
with a PASI score of 2.8 ± 2.4 and a BSA of 4.0 ± 2.8%. 
The DLQI score in the mild group (PASI < 10 and BSA 
< 10) compared to the moderate-severe group (PASI or 
BSA≥ 10) was 2.4 ± 2.7 vs. 4.9 ± 5.2, respectively. No 
significant differences were found between patients 
with mild and moderate–severe psoriasis in terms of the 
different demographic variables or regarding tobacco or 
alcohol consumption (Table SI1).
Psycho-emotional evaluation
The presence of psycho-emotional comorbidities (34%) 
or psychiatric disorders (28%) was detected in 49% of 
patients regardless of skin disease severity (Table SI1). No 
differences between patients with mild or moderate–se-
vere psoriasis, with regard to previous history of psycho-
emotional or psychiatric disorders, were detected, except 
for the need for current medical treatment in psychiatric 
patients with severe psoriasis (Table SI1). Males were 
less susceptible to symptoms of anxiety or depression 
than females but reported a greater impact on the QoL. 
Depression scores (HAD, HRSD and MADRS scales)
Differences in depression scores, related to psoriasis 
severity, were found. HAD score for depression for all 
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2 with a mean of 3.24, for patients with mild psoriasis 
and 3.38 for those with moderate-severe disease (Table 
I). We did not find any significant differences in the HAD 
depression questionnaire in relation to the skin disease 
severity, measured either by PASI or BSA, but patients 
with severe DLQI showed a higher risk of depression 
with an odds ratio (OR) of 3.51 (95% CI 1.32–9.30) for 
the highest tertile of HAD scores (Table II, Fig. 1 and 
Table SII1).
The level of depression was much higher in the mode-
rate–severe than in the mild group, both in the MADRS 
and HRSD. When applying HRSD scale, we observed 
significant differences in depression symptoms between 
mild (mean ± SD 4.73 ± 0.40) and moderate-severe disease 
(6.18 ± 0.41) (p-value < 0.01) (Table I). Interestingly, 
psoriasis severity showed a clear trend associated with 
higher scores in the MADRS in all evaluated severity 
indexes (mean ± SD 6.75 ± 0.45 for moderate–severe vs. 
5.13 ± 0.49 for mild psoriasis, p = 0.0018) (Tables I and 
II and Fig. 1). Moreover, skin severity indexes showed a 
significant trend in a dose-response manner, i.e., the more 
severe patients trend towards a higher risk for depression 
features (Fig. 1, Table SII1). These data may indicate that 
MADRS test could be the most accurate one to evaluate 
depression risk associated with psoriasis.
Anxiety evaluation (HAD, STAI scales)
Overall, anxiety commonly affects psoriatic patients, and 
individuals with more severe disease had worse scores 
on the anxiety questionnaires (Table I). HAD score for 
anxiety in all evaluated psoriasis patients disclosed a 
mean ± SD value of 6.25 ± 4.33 and no significant dif-
ferences were found regarding skin disease severity 
in the univariate analysis. Conversely, in the adjusted 
model, these scores show that patients with severe pso-
riasis have a higher risk of anxiety compared to those 
with mild disease (Table SII1). STAI questionnaires also 
detected a high risk for anxiety in patients with psoriasis 
(mean ± SD 16.83 ± 8.61) and revealed differences regar-
ding those presenting with mild or moderate–severe skin 
complaints (p-value < 0.02) (Tables I and II, and Table 
SII1), indicating that STAI test could be an interesting 
and reliable tool for evaluation of anxiety symptoms in 
patients with psoriasis.
Life events scale (Holmes-Rahe’s questionnaire)
Patients often acknowledged psychologically stressful 
life events in the last year, prior to the beginning of the 
study. Twenty-three percent of cases reported a low 
score in stressful events with less than 130 points, 43% 
recorded a score between 130 and 280 and 35% reported 
important stressful events with a total score higher than 
300. There were no significant differences in the mean 
score of stressful events between mild and moderate–
severe disease (Tables I and II). Moreover, we grouped 
the stressful events into aggravating or improvement 
categories (data not shown) and we did not find any 
significances, regarding skin disease severity.
DISCUSSION
Mood and affective disorders are frequently observed in 
patients with dermatological diseases and psychological 
or psychiatric co-morbidities have been found in up to 
40% of psoriatic patients (19, 20). Psoriasis, as a disease 
causing a significant impact on the physical aspect, may 






Mean ± SD p-value
HAD-Anxiety 6.23 ± 0.41 6.26 ± 0.31 0.954
HAD-Depression 3 ± 0.38 3.38 ± 0.25 0.376
Life Event Scale 235 ± 14 258 ± 12 0.221
HRSD 4.73 ± 0.40 6.18 ± 0.41 0.017
MADRS 5.13 ± 0.49 6.75 ± 0.45 0.018
State Anxiety Inventory 15.45 ± 0.70 17.75 ± 9.20 0.027
Trait Anxiety Inventory 18.60 ± 0.93 19.35 ± 11.39 0.567
Psoriasis Disability Index   0.98 ± 0.18 2.03 ± 0.35 0.022
Physical Component Summary 50.40 ± 0.85 48.65 ± 0.74 0.130
Mental Component Summary   0.749 0.750 0.751
Data adjusted for age, sex, education, alcohol, smoking, systemic treatment/
phototherapy, current pyschological/psychiatric treatment.
SD: Standard Deviation; HAD: Hospital Anxiety and Depression Scale; HRSD: 
Hamilton Rating Scale for Depression; MADRS: Montgomery-Asberg Depression 
Rating Scale. Significant values are shown in bold.
Table II. Different indexes of psycho-emotional disorders and stress level measurements according to the psoriasis severity variables
PASI (≥ 10)
OR (95% CI)
BSA (≥ 10) 
OR (95% CI)
DLQI (≥ 10) 
OR (95% CI)
Specific localized 
forms of psoriasisa 
OR (95% CI)
Hospital Anxiety and Depression Scale – Depression 1.52 (0.89–2.61) 1.12 (0.67–1.88) 2.70 (1.21–6.03) 0.87 (0.53–1.42)
Montgomery-Asberg Depression Rating Scale 1.51 (0.86–2.63) 1.00 (0.59–1.72) 1.84 (0.83–4.06) 0.78 (0.47–1.31)
Hamilton Rating Scale for Depression 1.26 (0.72–2.21) 1.33 (0.77–2.28) 1.14 (0.53–2.48) 0.72 (0.43–1.22)
Hospital Anxiety and Depression Scale – Anxiety 1.26 (0.70–2.28) 0.97 (0.55–1.70) 1.68 (0.74–3.83) NA
Life Event Scale (≥ 130) 1.55 (0.81–2.95) 1.62 (0.88–2.98) 1.19 (0.49–2.89) 1.62 (0.89–2.94)
State Anxiety Inventory 1.18 (0.68–2.06) 1.22 (0.72–2.06) 2.52 (1.16–5.50) 1.29 (0.78–2.14)
Trait Anxiety Inventory 1.01 (0.58–1.77) 0.77 (0.44–1.32) 1.87 (0.87–4.00) 0.74 (0.44–1.25)
Psoriasis Disability Index (>0) 0.60 (0.32–1.09) 0.84 (0.48–1.47) 2.27 (1.08–4.76) 1.31 (0.78–2.24)
Physical Component Summary 0.94 (0.55–1.62) 1.03 (0.61–1.76) 0.57 (0.27–1.18) 0.92 (0.56–1.53)
Mental Component Summary 0.81 (0.47–1.39) 1.36 (0.80–2.30) 0.64 (0.31–1.34) 1.02 (0.61–1.68)
aScalp and facial, palmo-plantar or genital psoriasis.
Data adjusted for age, sex, education, alcohol, smoking, systemic treatment/phototherapy, current pyschological/psychiatric treatment. 
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cause disturbances in the functional aspects and affect 
patients’ self-esteem (21, 22). Importantly, several stu-
dies have pointed out that psoriatic patients are more 
prone to develop depression or have suicidal ideation in 
comparison with the general population (23). In view of 
the influence of psychological factors on the evolution 
of psoriasis, there have been numerous research studies, 
assessing the effects of psychological therapies, (24, 25) 
including hypnosis (26), biofeedback (27, 28) and treat-
ments for stress, anxiety or depression (29, 30).
Based on reliable structured psychiatric interviews, 
with the use of structured questionnaires, we compared 
the frequency of anxiety, depression and stress levels 
in patients suffering from psoriasis, with regards to the 
severity and subtypes of the skin disease. In our study, we 
found higher levels of depression and anxiety attributes 
in patients, suffering from severe forms of psoriasis.
The detailed analysis of PASI, BSA and DLQI showed 
a significant relationship between depression and anxiety 
scales and the burden of psoriasis (31). In addition, the 
prevalence of mental disorders was significantly higher 
in patients with psoriasis, especially in those with higher 
disease severity; which would suggest that this ‘at risk’ 
population requires closer attention and possibly more 
intense therapeutic interventions in the management of 
their emotional disturbances. 
Depression status was evaluated with MADRS, HRDS 
or HAD depression scales and we found that patients with 
the more severe psoriatic disease have a higher degree 
of depression and psoriasis severity increases, more than 
two-fold, the risk for developing depression features in 
our series. Differences within depression scores related 
to psoriasis severity were found. Particularly, MADRS 
rating for depression was the most sensitive questionn-
aire, in detecting pathological worries in patients with 
severe skin disease when measured by PASI or BSA. In 
addition, these scores have been reported to detect that 
people with psoriasis have a higher risk of depression 
compared with people without the skin disease. Psoria-
tic patients from our population showed higher scores 
in HRSD and MADRS than those  in a non-psoriatic 
population (32–35).
Both patient groups had high mean anxiety scores; 
however, we found that patients with moderate–severe 
psoriasis have higher mean scores in anxiety tests. The 
highest adjusted OR for anxiety was found in STAI tests 
among patients with higher psoriasis severity (assessed 
with DLQI), which indicates that the risk of neurotic 
symptoms increases in patients with severe psoriasis. 
Emotional stress is considered as one of the psy-
chological variables most commonly related to health. 
Psoriatic patients and physicians commonly associate 
stress or worry with the course of the disease. Psoriasis 
is associated with poor life satisfaction, affective expres-
sion and psychological well-being, as well as anxiety or 
depression (36). However, there is limited and conflicting 
evidence concerning the role of psychological stress in 
relation to the onset or exacerbation of psoriasis (5). 
Clearance of psoriasis may improve stress, patients’ well-
being, anxiety or depression symptoms. Some studies 
have shown that patients with severe psoriasis have pro-
gressively adapted to the impact of the disease (37, 38).
Several studies have demonstrated that psoriasis 
is associated with stress in more than half of patients 
(39). LES is the most frequently used questionnaire for 
measuring levels of emotional stress (9). In our series, 
adjusted ratings for variables, considered as aggravating 
or improving factors in stressful life events within one 
preceding year, disclosed that most psoriatic patients 
(76%) suffered from moderated to high levels of stress. 
This observation reinforces the role of stress in the patho-
genesis of psoriasis. Stressful life events may represent 
not only a cause but also an effect and could explain the 
lack of differences observed in relationship to psoriasis 
severity or in cases with specific anatomical localizations 
(palmo-plantar or facial and scalp psoriasis).
DLQI scores change significantly with the clinical 
activity of psoriasis and can aid decision-making in the 
patient management. Perception of illness by patients 
does not always coincide with the objective measure-
Fig. 1. Risks of having psycho-emotional symptoms according psoriasis severity variables. Odds ratio and 95% confidence interval and indication 
of dose-response for the different indexes of psycho-emotional disorders and stress level and measurements of psoriasis severity. PASI: Psoriasis Area 
Severity Index; BSA: Body Surface Area; DLQI: Dermatology Life Quality Index; HAD: Hospital Anxiety and Depression Scale; LES: Life Event Scale; 
HRSD: Hamilton Rating Scale for Depression; MADRS: Montgomery-Asberg Depression Rating Scale; SAI: State Anxiety Inventory; TAI: Trait Anxiety 
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ments of psoriasis clinical severity (40). In our series, the 
DLQI test is associated with the emotional disturbances 
in different indexes. Impact on the functional aspects of 
patients was also observed in relation to the skin severity. 
In our experience, PDI test seems to be a more accurate 
tool, when evaluating functional impact of psoriasis, in 
comparison to SF-12 (both PCS and MCS) questionnai-
res. PDI is closely related to the QoL impairments and we 
have not found differences regarding either the extension 
of the skin disease or the presence or absence of specific 
localized forms of psoriasis. 
In conclusion, our study suggests the presence of a 
significant relationship between emotional disturbances 
and severity of the disease. We detected a remarkable im-
pact of psoriasis on functional activity and QoL. Stress, 
not only secondary to psychological disorders but also 
in relation to recent stressful events, is commonly repor-
ted in psoriatic patients. Recognition of the association 
between stress and psoriasis seems to be an important 
factor that should be considered in their management. 
These data reinforce the notion that psycho-emotional, 
functional and QoL interventions can therefore be di-
rected more appropriately, especially for patients with 
moderate–severe disease. 
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